Skip to content

Trinity Nuclein Series C QP Investors

6 viewers · 30d

Total raised

$1.0M

1 filing since 2025 · latest Fund filed

Cumulative raised
LAST ROUND
Fund · $1.0M
ROUNDS
1
INVESTORS
11
FOUNDED
2025
HQ
Southlake, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
6

AI overview

Updated

Trinity Nuclein Series C QP Investors LLC is an investment entity associated with Trinity Investors, a distinguished private equity firm. This vehicle is primarily aimed at funding Nuclein, a biotechnology innovator dedicated to creating advanced rapid diagnostic testing solutions for infectious diseases.

What sets it apart

Trinity Nuclein stands out by enabling healthcare providers to obtain rapid, lab-quality diagnostic results in just 15 minutes, significantly reducing the waiting times associated with traditional testing methods.

Funding history

1 round
Fund+1Feb 18, 2025 · $75K min
Form D
+$1.0M$1.0M total

Latest SEC filings

via EDGAR · CIK 0002055837
Form D · Feb 18, 2025View on EDGAR

Products

1 tracked

DASH® Rapid PCR System

Rapid Diagnostics

The DASH® Rapid PCR System is a cutting-edge diagnostic tool that delivers highly accurate PCR test results within a mere 15 minutes, suitable for use at the point of care. It addresses the complexities and delays of conventional diagnostic testing by offering rapid and highly reliable results in a variety of healthcare settings.

  • Fast results comparable to traditional antigen tests
  • Low-cost diagnostics with high sensitivity and specificity
  • Robust multiplexing capabilities across different sample types
  • Less than one minute of hands-on preparation time